Susan Mary Galbraith
Corporate Officer/Principal bij ASTRAZENECA PLC
Profiel
Susan Mary Galbraith is currently the Director at the American Association for Cancer Research and the Executive VP-Oncology Research & Development at AstraZeneca PLC.
Previously, she served as an Independent Non-Executive Director at Horizon Discovery Group Ltd.
from 2014 to 2020, a Member-Supervisory Board at BB Biotech AG from 2020 to 2021, and the Vice President-Oncology & Clinical Biomarkers at Bristol-Myers Squibb Pharmaceuticals Ltd.
in 2010.
She holds an undergraduate degree from The University of Manchester, a graduate degree from the University of Cambridge, and a doctorate from the University of London.
Actieve functies van Susan Mary Galbraith
| Bedrijven | Functie | Begin |
|---|---|---|
| ASTRAZENECA PLC | Corporate Officer/Principal | 01-01-2010 |
American Association for Cancer Research
 American Association for Cancer Research Miscellaneous Commercial ServicesCommercial Services American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA. | Director/Board Member | 01-01-2021 |
Eerdere bekende functies van Susan Mary Galbraith
| Bedrijven | Functie | Einde |
|---|---|---|
| BB BIOTECH AG | Director/Board Member | 02-07-2021 |
| HORIZON DISCOVERY GROUP PLC | Director/Board Member | 30-04-2020 |
Bristol-Myers Squibb Pharmaceuticals Ltd.
 Bristol-Myers Squibb Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb Pharmaceuticals Ltd. manufactures pharmaceutical products. Its products are used for treatment of diseases like cancer, diabetes, arthritis, hepatitis, and psychiatric disorders. The company distributes products throughout the United Kingdom. Bristol-Myers Squibb Pharmaceuticals was founded in 1989 and is located in Uxbridge, UK. | Corporate Officer/Principal | 01-01-2010 |
Opleiding van Susan Mary Galbraith
| The University of Manchester | Undergraduate Degree |
| University of Cambridge | Graduate Degree |
| University of London | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| BB BIOTECH AG | Finance |
| ASTRAZENECA PLC | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Bristol-Myers Squibb Pharmaceuticals Ltd.
Bristol-Myers Squibb Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb Pharmaceuticals Ltd. manufactures pharmaceutical products. Its products are used for treatment of diseases like cancer, diabetes, arthritis, hepatitis, and psychiatric disorders. The company distributes products throughout the United Kingdom. Bristol-Myers Squibb Pharmaceuticals was founded in 1989 and is located in Uxbridge, UK. | Health Technology |
American Association for Cancer Research
American Association for Cancer Research Miscellaneous Commercial ServicesCommercial Services American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA. | Commercial Services |
Horizon Discovery Group Ltd.
 Horizon Discovery Group Ltd. Medical SpecialtiesHealth Technology Horizon Discovery Group Ltd. is a cell engineering company, which engages in the design and engineering of genetically-modified cells. The firm operates through the following business segments: Products, Services, and Leveraged Research & Development. The Products segment sells cell lines and other products. The Services segment offers cell line manufacturing services. The Leveraged Research & Development segment business unit is operated on a portfolio basis. It serves pharmaceutical, biotechnology, and diagnostic companies. The company was founded by Christopher John Torrance, Adam John Collier, and Alberto Bardelli in July 2005 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
